Earlier Use of ICIs in NSCLC: Integrating the Latest Evidenc

Earlier Use of ICIs in NSCLC: Integrating the Latest Evidence Into Clinical Practice

3 episodes
1.00 program credits
59m
MinuteCE®
ReachMD Healthcare Image
Details
Episodes
Documents
Presenters
Comments
  • Overview

    The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria. 

    Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists and thoracic surgeons, as well as other clinicians involved in the management of patients with NSCLC.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Apply the latest evidence to optimize the use of neoadjuvant immunotherapy treatment options to improve outcomes of patients with resectable NSCLC
    • Apply the latest evidence to optimize the use of adjuvant immunotherapy treatment options to improve outcomes of post-resection NSCLC patients
    • Evaluate current and emerging evidence to inform patient selection and treatment strategies with perioperative immunotherapy in early-stage NSCLC
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Joshua E. Reuss, MD, faculty for this educational event, receives research funds from Genentech/Roche, Nuvalent, and Verastem and receives consulting fees from Genentech/Roche, Sanofi/Genzyme, Personalis, Guardant, AstraZeneca, BMS, Arcus, Abbvie, and Merck.  

    Jessica S. Donington MD, MSCR, faculty for this educational event, receives consulting fees from 
    AstraZeneca, Bristol Myers Squibb, Genentech, Inc./F. Hoffmann-La Roche Ltd., Merck & Co., Inc and AMGEN

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    Total CME, LLC., planners, and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Commercial Support

    This activity is supported by independent educational grants from Merck Sharp & Dohme LLC and Bristol Myers Squibb.

  • Instructions for Completion

    During the period 11/30/2023 through 11/30/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Register

We’re glad to see you’re enjoying MedEd On The Go…
but how about a more personalized experience?

Register for free